XOMA Corporation (NASDAQ:XOMA) has been given a $38.00 price objective by stock analysts at HC Wainwright in a report issued on Tuesday. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 24.59% from the stock’s current price.
Several other brokerages have also recently weighed in on XOMA. Zacks Investment Research upgraded shares of XOMA Corporation from a “hold” rating to a “strong-buy” rating and set a $33.00 price target on the stock in a research note on Friday. Wedbush upgraded shares of XOMA Corporation from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $9.00 to $19.00 in a research note on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $30.00.
Shares of XOMA Corporation (NASDAQ XOMA) opened at $30.50 on Tuesday. XOMA Corporation has a fifty-two week low of $3.96 and a fifty-two week high of $33.00. The company has a debt-to-equity ratio of 3.53, a current ratio of 3.45 and a quick ratio of 3.45.
Several hedge funds have recently made changes to their positions in XOMA. EAM Investors LLC bought a new stake in shares of XOMA Corporation during the 3rd quarter valued at $835,000. OxFORD Asset Management LLP bought a new stake in shares of XOMA Corporation during the 3rd quarter valued at $543,000. Finally, California Public Employees Retirement System raised its position in shares of XOMA Corporation by 95.5% during the 1st quarter. California Public Employees Retirement System now owns 21,780 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 10,640 shares during the period. Hedge funds and other institutional investors own 30.69% of the company’s stock.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.